VEGFA and neoplasm: However, the overall results also indicate limitations of intravitreal anti-VEGF treatment as monotherapy: first, an effective dose required for JRCHs may need to be higher than the dose required for the treatment of choroidal neovascularization; and second, the route of administration through the vitreous may limit the access to tumor cells in the interior of a large endophytic lesion (22).